RESEARCH · TESAMORELIN · MUSCLE, LIPIDS AND MARKERS
Tesamorelin Beyond Visceral Fat Volume: Skeletal Muscle, Fat Density, Lipids and Inflammatory Markers
PurixLab’s Tesamorelin 5mg is a research vial of the stabilised GHRH(1-44) analogue. Our earlier articles cover a research overview, visceral fat and liver fat, pharmacokinetics and GH pulsatility and a comparison with other GH secretagogues. Most tesamorelin headlines focus on how much visceral fat is lost. This article looks at what else the trials measured: skeletal muscle area and density, the quality of the remaining fat, blood lipids, and inflammatory, fibrinolytic and vascular markers. These are published findings from clinical research under medical supervision; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Lipids in the phase 3 programme
Lipids were secondary endpoints from the start. In the first phase 3 trial, 412 people with HIV and abdominal fat accumulation were randomised to tesamorelin or placebo for 26 weeks. Visceral fat fell by 15.2% versus a 5.0% increase with placebo, triglycerides decreased by 50 mg per decilitre versus an increase of 9, and the total-to-HDL cholesterol ratio decreased by 0.31 versus an increase of 0.21. IGF-I rose by 81.0%, and glycaemic measures did not differ significantly between groups [1]. The second pivotal trial (404 patients) confirmed the visceral fat reduction, reported roughly 18% loss in those continuing for 12 months, and found that the initial improvements were rapidly lost in those switched to placebo [2].
A later post hoc analysis asked whether metabolic changes tracked fat loss. Among tesamorelin-treated participants, responders, defined a priori as those with at least 8% visceral fat reduction, had larger triglyceride decreases than non-responders (-0.6 versus -0.1 mmol/L at 26 weeks; -0.8 versus 0.0 mmol/L at 52 weeks), better-preserved glucose measures and improved adiponectin [3]. Pooled phase 3 data also showed that baseline metabolic syndrome and triglycerides above 1.7 mmol/L were associated with a greater likelihood of response [4]. Two 2026 meta-analyses summarise the randomised evidence: one of four trials (909 patients) found a modest total cholesterol reduction of 0.16 mmol/L [5], and one of five trials reported a lean body mass increase of 1.42 kg without perturbation of glucose [6].
Inflammatory, fibrinolytic and immune markers
In 410 patients from the phase 3 programme, visceral fat at baseline correlated with PAI-1, tPA, CRP and (inversely) adiponectin. Tesamorelin produced a significant decrease in tPA antigen versus placebo, but changes in PAI-1 were not significant, and the authors describe the effects on adiponectin and fibrinolytic markers as modest and associated with visceral fat change [7].
A more detailed picture came from a 12-month trial in 61 people with HIV and fatty liver disease. Of 92 immune, chemotaxis and metabolic biomarkers measured, 13 proteins decreased with tesamorelin and none increased, including chemokines and T-cell associated molecules, and targeted transcriptomics on liver biopsies showed down-regulated immune activation pathways [8]. This is a proteomic signal in a specific population, not evidence of an effect on clinical immune outcomes.
A vascular marker in people without HIV
Most tesamorelin data come from people with HIV. One exception is a 12-month randomised trial in 60 abdominally obese adults with reduced GH secretion. Compared with placebo, tesamorelin reduced visceral fat without changing abdominal subcutaneous fat and improved triglycerides (treatment effect -37 mg/dl), log C-reactive protein and carotid intima-media thickness (treatment effect -0.04 mm). IGF-I increased, and no changes in fasting glucose, 2-hour glucose or glycated haemoglobin were seen [9]. Carotid intima-media thickness is an imaging marker, not a cardiovascular event, and the study was small.
Skeletal muscle and fat quality
Computed tomography scans taken for visceral fat also capture trunk muscle. In an exploratory secondary analysis of two previously completed randomised trials, restricted to tesamorelin responders (n=193) and placebo participants (n=148), tesamorelin was associated with greater increases in the density of four truncal muscle groups (1.56 to 4.86 Hounsfield units) and in lean muscle area (0.64 to 1.08 cm2) [10]. The authors read higher muscle density on CT as less fat within the muscle, as reflected in the title of the paper [10].
The same image set was used to measure fat density. Over 26 weeks, visceral fat density increased by 6.2 Hounsfield units with tesamorelin versus 0.3 with placebo, and subcutaneous fat density by 4.0 versus 0.3, and these effects persisted after controlling for the change in fat area [11]. The authors interpret greater density as smaller, higher-quality adipocytes, but CT density is an indirect measure.
Muscle function has been probed too. In 39 obese adults with reduced GH secretion, phosphocreatine recovery after submaximal exercise, a magnetic resonance spectroscopy marker of mitochondrial function, improved in proportion to the rise in IGF-I (R=0.56) [12]. This is a correlation within a small trial rather than a direct treatment comparison.
A trial designed for physical function
None of the studies above measured physical function as a primary endpoint. A newly published protocol, also named TRIUMPH (Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV), plans to randomise 100 sedentary adults aged 50-80 years with HIV and excess abdominal fat to tesamorelin or placebo alongside home-based exercise for 24 weeks, followed by a 24-week extension, with physical function, muscle content and quality, muscle fat and mitochondrial function among the endpoints [13]. (It is unrelated to the retatrutide TRIUMPH trials.)
Reading this literature critically
- Responder-only analyses. The muscle and fat-density studies compared responders with placebo, which can overstate the average treatment effect [10,11].
- Post hoc design. Several analyses were secondary or post hoc rather than pre-specified [3,10].
- Population. Most data come from people with HIV on antiretroviral therapy; only small trials have studied obesity without HIV [9,12].
- Tolerability. Meta-analyses note growth hormone-related adverse effects such as arthralgia and myalgia, and a trend toward higher discontinuation [6,5].
What remains open
- Whether muscle density and lipid changes translate into better physical function or fewer cardiovascular events.
- How much of each effect is mediated by visceral fat loss versus a direct action of the GH/IGF-I axis.
Tesamorelin 5mg at PurixLab
Tesamorelin 5mg: a labelled lyophilized research vial with 5mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tesamorelin-5mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PubMed 18057338 · doi:10.1056/NEJMoa072375
- Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22. PubMed 20101189 · doi:10.1097/QAI.0b013e3181cbdaff
- Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-51. PubMed 22495074 · PMC3348954 · doi:10.1093/cid/cis251
- Mangili A, Falutz J, Mamputu JC, et al. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One. 2015;10(10):e0140358. PubMed 26457580 · PMC4601733 · doi:10.1371/journal.pone.0140358
- Ditta AM, Naeem RM, Sami MM, et al. Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis. J Int Assoc Provid AIDS Care. 2026;25:23259582261475549. PubMed 42538058 · PMC13428105 · doi:10.1177/23259582261475549
- Badran AS, Helal A, Shata KS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. PubMed 41545261 · doi:10.1016/j.orcp.2026.01.002
- Stanley TL, Falutz J, Mamputu JC, et al. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011;25(10):1281-8. PubMed 21516030 · PMC3673013 · doi:10.1097/QAD.0b013e328347f3f1
- Stanley TL, Fourman LT, Wong LP, et al. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021;73(4):621-630. PubMed 33852720 · PMC8366828 · doi:10.1093/cid/ciab019
- Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-79. PubMed 23015655 · PMC3513535 · doi:10.1210/jc.2012-2794
- Adrian S, Scherzinger A, Sanyal A, et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. PubMed 31237318 · PMC6766405 · doi:10.14283/jfa.2018.45
- Lake JE, La K, Erlandson KM, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. PubMed 33756511 · PMC8243807 · doi:10.1097/QAD.0000000000002897
- Makimura H, Murphy CA, Feldpausch MN, et al. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. J Clin Endocrinol Metab. 2014;99(1):338-43. PubMed 24178787 · PMC3879673 · doi:10.1210/jc.2013-3436
- Erlandson KM, Gustafson L, Johnson JE, et al. Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. BMJ Open. 2026;16(7):e120740. PubMed 42419889 · PMC13347827 · doi:10.1136/bmjopen-2026-120740